Evidence map›Paper›PMID 40523956›Full record

ArticleNPJ precision oncology2025

A temporal model of tumor-immune dynamics during the metastatic progression of high-grade serous ovarian cancer.

Donagh Egan, Kate Glennon, Ann Treacy, Aurelie Fabre, Janet McCormack, Salisha Hill, Ryan Morrison, Vadim Zhernovkov, Daniel Liebler, Walter Kolch and 1 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. γδ T cells and cancer.The Journal of clinical investigation · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Donagh EganSystems Biology Ireland, University College Dublin, School of Medicine, Belfield, Dublin 4, Dublin, Ireland. donagh.egan@ucdconnect.ie.
Kate GlennonUCD-Gynaecological Oncology Group, School of Medicine, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland.
Ann TreacyDepartment of Pathology, Mater Misericordiae University Hospital, Dublin, Ireland.
Aurelie FabreResearch Pathology Core Facility, Conway Institute, University College Dublin, Dublin, Ireland.
Janet McCormackResearch Pathology Core Facility, Conway Institute, University College Dublin, Dublin, Ireland.
Salisha HillInotiv Inc, Nashville, Tennessee, Ireland.
Ryan MorrisonInotiv Inc, Nashville, Tennessee, Ireland.
Vadim ZhernovkovSystems Biology Ireland, University College Dublin, School of Medicine, Belfield, Dublin 4, Dublin, Ireland.
Daniel LieblerInotiv Inc, Nashville, Tennessee, Ireland.
Walter KolchSystems Biology Ireland, University College Dublin, School of Medicine, Belfield, Dublin 4, Dublin, Ireland.
Donal BrennanSystems Biology Ireland, University College Dublin, School of Medicine, Belfield, Dublin 4, Dublin, Ireland.

Funding

Science Foundation Ireland 18/SPP/3522
6 · The paper itself

Abstract

Patients with high-grade serous ovarian cancer (HGSOC) typically present with widespread metastasis, obscuring a temporal understanding of tumor-immune dynamics. To address this, we perform multi-site global proteomics alongside matched immunohistochemistry (IHC) for CD4⁺ and CD8⁺ tumor-infiltrating lymphocytes (TILs) in patient samples. We order the protein expression profiles using an unbiased pseudotime analysis, recapitulating clinical observations of metastatic progression, and providing a framework to explore tumor-immune dynamics from localized to metastatic disease. Metastatic progression correlates with immune cell infiltration, the recruitment of regulatory T cells (Tregs) to counterbalance γδ T cell abundance, and an increased abundance of exhausted CD8⁺ T cells. The accumulation of Tregs at metastatic sites correlates with SNX8 expression, a critical regulator of the STING pathway. In early-stage tumors, keratin-expressing cancer cells recruit Tregs via MHC class II, fostering an inflammatory phenotype with limited IFNγ production and non-clonally expanded T cells. Together, our findings reveal novel mechanisms of immune escape associated with both localized disease and metastatic progression in HGSOC.

Identifiers

PMID40523956
PMCPMC12170838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.